Weight Loss Investigational 🔥 Trending

Mazdutide

A GLP-1 and glucagon dual agonist developed with Innovent and Lilly, notable for obesity data and approval progress in China.

GLP-1GlucagonObesityInvestigationalChina

Also referenced as: IBI362, LY3305677

Also appears in: Hormone

Price compare
9 tracked offers across 9 vendors · 6 dosages
Best trust-adjusted value: Southern Aminos · Moderate trust · $4.86/mg
From
$4.86/mg
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Weight Loss

Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.

Aliases
2

IBI362, LY3305677

Signal depth
Medium

No FDA label signal · 36 trials · 46 PubMed results

Promising
Research evidence

Mazdutide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Mazdutide has 31 name-matched clinical trials (highest phase: Phase 4) and 46 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
PHASE4 · Randomized Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) PHASE4 · Randomized Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity PHASE3 · Randomized A Study of IBI362 in Participants With Type 2 Diabetes Nature Communications · 99 citations A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity New England Journal of Medicine · 81 citations Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight Diabetes Care · 76 citations Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What mazdutide is

Mazdutide is a GLP-1 / glucagon dual receptor agonist developed by Innovent and Lilly, best known right now for obesity and metabolic-disease development in China.

Why it matters

It belongs in the same broad family as other dual-agonist obesity drugs, but it matters on its own because it already has a meaningful clinical literature and has moved farther commercially in China than many pipeline names discussed in U.S.-centric peptide circles.

Regulatory context

Mazdutide is not FDA approved in the United States. It is best understood as an important international obesity-pipeline drug rather than an established U.S. therapy.

Practical reading note

Mazdutide is useful because it helps the library track not just what is popular in the U.S. market, but what is becoming important globally.